ProJect Pharmaceutics is proud to have contributed with its services, expertise and knowledge to develop a lyophilized i.v. injection formulation for one of its clients’ drug products which was approved by the U.S. Food and Drug Administration (FDA). Goal of the development was to move from an oral administration of the drug to an injectable
ProJect Pharmaceutics receives CIR application (Research Tax Credit) for the benefit of its French customers
ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. Expanding the offering of its service portfolio towards the French customer base, ProJect Pharmaceutics was engaged to apply at the French Ministère de L’Enseignement Supérieur, De La Recherche Et De L’Innovation for eligibility to join
Dear customers of ProJect Pharmaceutics, We understand that all of us are facing exceptional times due to the Corona pandemic. Knowing about the important role our employees play in our customers projects for developing innovating therapeutics, we try to deliver in these challenging times as much as possible, on-site as well as from home office.
Join ProJect Pharmaceutics at Gene and Cell Therapy_Quality Developments to Commercialization Summit 2019
ProJect Pharmaceutics is delighted to exhibit at the upcoming Gene and Cell Therapy_Quality Developments to Commercialization Summit, taking place in Berlin, Germany, June 5-6, 2019. We look forward to welcoming you at our booth.